ATX-304 (formerly O304) vs SLU-PP-332
updated
ATX-304 (formerly O304) (tier B) vs SLU-PP-332 (tier C): what each is, half-life and source counts side by side.
ATX-304 (formerly O304) · tier B
an investigational oral AMPK activator with one small randomized diabetes trial, a newer obesity pilot, and an animal pharmacokinetic curve that cannot establish a human dosing interval.
tier rationale
B reflects a 65-person, 28-day diabetes trial and a 23-person, eight-week obesity and prediabetes study with measurable metabolic effects. Neither study established weight-loss efficacy or safety at weight-loss doses.
SLU-PP-332 · tier C
SLU-PP-332 is a small-molecule pan-ERR agonist with mouse endurance and metabolic results, ex vivo human myoblast work, no oral bioavailability, and no human administration study.
tier rationale
C-tier reflects direct and repeated preclinical findings with no human administration evidence.
at a glance
| ATX-304 (formerly O304) | SLU-PP-332 | |
|---|---|---|
| tier | B | C |
| category | weight loss | weight loss |
| sources | 6 | 12 |
| claims evaluated | 4 | 3 |
| half-life | human terminal half-life not published; approximately 11 hours shown only as a low-confidence mouse apparent-decline proxy | no numeric human or animal concentration-time curve retained |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.